News room

Egetis is an innovative and integrated pharmaceutical company, focusing on projects in late-stage development for commercialization for treatments of serious diseases with significant unmet medical needs in the orphan drug segment

PledPharma appoints Yilmaz Mahshid as new CFO

November 7, 2017

PledPharma AB
Company Announcement

PledPharma appoints Yilmaz Mahshid as new CFO

Stockholm, 2017-11-07 08:00 CET (GLOBE NEWSWIRE) -- 
PledPharma AB announces today that Yilmaz Mahshid has been appointed to the
position as Chief Financial Officer. Yilmaz joins in December from
Industrifonden where he held the positions as Investment Manager & Controller. 

Yilmaz Mahshid (b. 1979) joins from the Life science team at Industrifonden,
where he held the position as Investment Manager & Controller and was
responsible/ board representative for two of the fund's holdings. Over the past
year, he has facilitated Industrifonden’s life science listings on Nasdaq
Stockholm's main market. He has previous experience from positions as
healthcare analyst at Pareto Securities and Öhman Fondkommission. Yilmaz also
has a solid academic background with a PhD from the Department of Medical
Biochemistry and Biophysics at the Karolinska Institute. He started his career
as a researcher at Karolinska institutet and after that at the pharmaceutical
companies Biolipox and Orexo. 

"We are pleased to welcome Yilmaz Mahshid to PledPharma. His extensive
experience and knowledge in financial management, business development,
investor relations and medical science makes him ideal in the role of CFO at
PledPharma, "says PledPharmas CEO Nicklas Westerholm. 

Yilmaz Mahshid will be part of PledPharma's leadership team and will report to
the CEO. The CFO position includes responsibility for the company's finance and
administration functions, investor relations as well as involvement in strategy
and business development. 

"I look forward to contributing to PledPharma’s continued work to create value
for its shareholders and all the patients who could benefit from the company's
innovative drug candidates against chemotherapy induced nerve damage and liver
damage caused by acetaminophen poisoning," says Yilmaz Mahshid. 

Yilmaz Mahshid is taking over from Michaela Gertz, who in December leaves the
company after seven years as CFO. PledPharma has since this summer strengthened
the leadership team by the recruitment of Dr. Stefan Carlsson, Chief Medical
Officer and Dr Christian Sonesson, Vice President Product Strategy and

For more information, please contact:

Nicklas Westerholm, CEO, phone: +46 73 354 20 62

About PledPharma

PledPharma develops new drugs that protect the body against oxidative stress –
a potentially debilitating and sometimes life-threatening condition that can be
caused by chemotherapy treatment and following acetaminophen (paracetamol)
overdose. The company's most advanced project PledOx® is being developed to
reduce nerve damage associated with chemotherapy. A phase IIb study has been
conducted and will serve as the basis for the continued development. The drug
candidate Aladote® is being developed to reduce the risk of acute liver failure
associated with acetaminophen poisoning. PledPharma (STO: PLED) is listed on
Nasdaq First North. Erik Penser Bank is the company’s Certified Adviser (tel
+46 8 463 80 00). For more information, see



Contact us

Address: Klara Norra Kyrkogata 26, SE 111 22 Stockholm, Sweden

Phone: +46 8 679 72 10